Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.

Jia WangJie ZuoAlafate WahafuMao-de WangRui-Chun LiWan-Fu Xie

Published in: CNS neuroscience & therapeutics (2019)

Combined elevation of TRIB2 and MAP3K1 could be novel prognostic biomarkers and potential therapeutic targets to evaluate the malignancy and long-term outcomes of GBM.

Keyphrases

poor prognosis
long non coding rna
high density
risk assessment
climate change
cancer stem cells